In this hybrid PET/MRI study with the second-generation tau PET tracer [18F]PI-2620, we provide evidence that phenotyping AD patients (i.e., aAD, lvPPA, PCA) is possible with regard to tau accumulation, relative brain perfusion, grey matter density, functional network alterations and microstructural white matter alterations. Here, MAPT is linked to Alzheimer disease.